Donna Przepiorka
- Hematology top 0.01%
- Hematopoietic Stem Cell Transplantation 103
- Acute Myeloid Leukemia Research 34
- Chronic Myeloid Leukemia Treatments 20
- Transplantation top 0.1%
- Renal Transplantation Outcomes and Treatments 20
- Genetics top 0.1%
- Immunology top 0.2%
- Immune Cell Function and Interaction 18
- Oncology top 0.2%
- Neutropenia and Cancer Infections 18
- Polyomavirus and related diseases 15
-
- Acute Lymphoblastic Leukemia research 23
- Co-authors
- Peyton MartinP BeattyDaniel WeisdorfJill HowsKlingemann HgThomas EdRichard E. ChamplinSergio Giralt
- Cited by
- HematologyTransplantationGenetics
- Partner nations
- United StatesFranceCanada
In The Last Decade
Donna Przepiorka
193 papers receiving 17.8k citations
Hit Papers
Peers
Comparison fields: 5 of 148
- Hematology 12.0k
- Transplantation 1.5k
- Genetics 3.0k
- Immunology 5.6k
- Oncology 5.5k
Countries citing papers authored by Donna Przepiorka
This map shows the geographic impact of Donna Przepiorka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Przepiorka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Przepiorka more than expected).
Fields of papers citing papers by Donna Przepiorka
This network shows the impact of papers produced by Donna Przepiorka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Przepiorka. The network helps show where Donna Przepiorka may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Donna Przepiorka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2022 | 14 | |
| 4 | 2021 | 57 | |
| 5 | 2019 | 93 | |
| 6 | 2019 | 102 | |
| 7 | 2019 | 91 | |
| 8 | 2019 | 65 | |
| 9 | FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemiabreakdown → | 2018 | 252 |
| 10 | 2018 | 221 | |
| 11 | 2018 | 98 | |
| 12 | FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndromebreakdown → | 2018 | 610 |
| 13 | 2018 | 189 | |
| 14 | 2018 | 44 | |
| 15 | 2015 | 261 | |
| 16 | Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. | 2002 | 119 |
| 17 | Clinical trials of HER-2/neu-specific vaccines. | 2000 | 28 |
| 18 | 1999 | 45 | |
| 19 | Allogeneic blood stem cell transplantation | 1997 | 12 |
| 20 | 1996 | 10 |
About Donna Przepiorka
Donna Przepiorka is a scholar working on Hematology, Transplantation and Genetics, having authored 197 papers that have together received 18.2k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (103 papers), Acute Myeloid Leukemia Research (34 papers), Acute Lymphoblastic Leukemia research (23 papers), Renal Transplantation Outcomes and Treatments (20 papers), Chronic Myeloid Leukemia Treatments (20 papers), Immune Cell Function and Interaction (18 papers), Neutropenia and Cancer Infections (18 papers) and Polyomavirus and related diseases (15 papers). The work is most often cited by research in Hematology (12.0k citations), Transplantation (1.5k citations) and Genetics (3.0k citations). Donna Przepiorka has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Peyton Martin, P Beatty, Daniel Weisdorf, Jill Hows, Klingemann Hg, Thomas Ed, Richard E. Champlin, Sergio Giralt, Börje S. Andersson and Paolo Anderlini. Their work appears in journals such as Nature, JAMA and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.